drugset / Trial / NCT01601522
Peanut Allergy Oral Immunotherapy Desensitization
Phase 2
Completed
43 enrolled
Hamilton Health Sciences Corporation
AllerGen NCE Inc. · collabMcMaster University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the study is to determine how a type of treatment for peanut allergy known as oral desensitization works in the immune system. Objectives 1. To determine whether premedication with desloratidine and ranitidine results in fewer side effects during desensitization procedure. 2. To assess quality of life in peanut allergic subjects before and after desensitization. 3. To compare serum metabolites in peanut allergic and non peanut allergic subjects.
Timeline
- Start
- 2012-02
- Primary completion
- 2021-09
- Completion
- 2021-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Desloratidine | Unknown | 2.5 mg | Oral |
| Subject | Ranitidine | Unknown | 75 mg | Oral |